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INTRODUCTION 
Diabetes mellitus is a metabolic disease; in which the body’s inability to 
synthesis   required   amount of insulin causes elevated levels glucose in the blood. 
Diabetes mellitus is due to either the pancreas not producing enough insulin or due 
to the cells of the body not responding properly to the insulin produced 
Hyperglycemia is due to decreased insulin secretion, decreased    glucose 
utilization in peripheral tissues,or due to more glucose production. Hyperglycemia 
due to many causes but is most commonly due to type 1 or type 2 diabetes1. 
Diabetes mellitus is a metabolic disorder, characterized by hyperglycemia caused 
by absolute or relative deficiency of insulin. The worldwide   prevalence of 
diabetes for all age groups was 2.8% in2000 and will be 4.4%2030. In the past two 
decade’s worldwide prevalence of diabetes mellitus   increased. As of 2014, an 
estimated 387 million people have diabetes worldwide   with type 2 diabetes 
making up about 90% of the cases. This represents 8.3% of the adult population. 
The prevalence   of   diabetes with equal rates in both women and men. From 2012 
to 2014, diabetes is estimated to have resulted in 1.5 to 4.9 million deaths each 
year. 2 Diabetes doubles a person's risk of death. The number of people with 
diabetes is expected to rise to 552 million by 2030.The prevalence of both types 
of diabetes   varies around   the world, and is due to differences in genetic and 
environmental factors. 
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Diabetes can affect more than 62 million Indians, which is more than 7% 
of adult population. The average age of onset of diabetes is 42 yrs. An estimate 
shows approximately 1 million Indians die due to diabetes every year. The 
prevalence was 2.1per cent in urban population and 1.5 per cent in the rural 
population3 while in those above 40 year of age, the prevalence was 5 per cent in 
urban and 2.8 percent in rural areas. The   International   Diabetes Federation   
estimates that the total number of diabetic patients to be around 40.9 million in 
India and this will become 69.9million by the year 2030. Although the prevalence 
of both type1 and type 2diabetes increasing; the prevalence of type2DM is  raising   
rapidly, because of obesity, sedentary life styles as country become more 
industrialized and increasing aging of population. The epidemic of diabetes is due 
to the rapid transition associated with change in dietary patterns and reduced 
physical activity as evident from more prevalence in   urban   population4. 
In a multifaceted country like ours, with various ethnicities, cultural and 
food patterns and above all with varied political  outlooks  on the  aspects  of  
health   coupled with significant  infrastructure limitations has effectively 
prevented us from having completely representative  comprehensive  surveys with  
regard to demography. 
The disease and death registration systems are in a state of shambles. This 
has been a big bane of our health care system and has prevented us from taking 
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pre-emptive measures. With a health care system as frail as ours   with numerous 
lacunae it becomes even more imperative to initiate cost-effective solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim of study 
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1. To assess risk factors of DKA admitted in intensive medical care unit 
2. To assess prognosis of DKA patients in intensive medical care unit. 
3. To assess duration of diabetes and the type of treatment patients had taken  
with outcomes of  DKA 
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REVIEW OF LITERATURE 
SYNTHESIS OF INSULIN 
Insulin is secreted by islets of beta cells in pancreas. The islets are scattered 
throughout the pancreas, they are more   found in the tail than in the body and 
head. Humans have 1 to 2 million islets 2% of the volume of the pancreatic gland 
consists of islets. Insulin is synthesized as a larger precursor polypeptide chain 
preproinsulin. It has 109 amino acids. It is rapidly converted to proinsulin in the 
endoplasmic reticulum by removal of leader sequence of 23 amino acids; which  
is   transported  into golgiapparatus where it is cleaved by a protease; an internal 
31-residue fragment cleaved from proinsulin produces the C peptide and the A 
chain( with -21 amino acids) and B chain( with -30 amino acids) of insulin5. The 
mature insulin molecule and c-peptide are keeping    together; both of them 
secreted from secretory granules in the beta cells. 
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STRUCTURE OF INSULIN 
Insulin is a protein hormone with 2 polypeptide chains. The A chain with 
21 aminoacids and B chain with 30 aminoacids are joined together by a pair of 
disulphidebonds. Removal of   sulphide   bridges cause loss of activity. 
 
Structure of insulin 
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SECRETION OF INSULIN 
Glucose is an important regulator of insulin secretion from pancreatic beta 
cells. In the pancreatic βcells; ATP sensitive potassium (k+) channel plays an 
important role in glucose-stimulated insulin secretion.  When   Glucose levels 
reaches 70 mg/dl; insulin production starts by translation and processing of 
proteins. It is affected by aminoacid, ketone bodies,   neurotransmitters, GIPs 
(Gastrointestinal peptide) etc. Insulin synthesis by Glucose stimulation; starts with 
SYNTHESIS OF INSULIN 
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its transport into the beta cell by a facilitative glucose transporter GLUT2.  Enzyme 
glucokinase   play an important role   for insulin secretion via glucose 
phosphorylation. Elevated blood glucose increases glucose metabolism in the β-
cell and elevates ATP. This metabolic signal close  KATP channels, causing    beta 
cell membrane depolarization; activation of voltage dependent  calcium channels,  
increased calcium entry, and insulin   exocytosis. 
ACTION OF INSULIN 
  Insulin   metabolism    takes place   in the liver. The half-life of insulin in 
the circulation in humans is about 5 min. It binds to insulin receptors, and some 
are internalized. It is destroyed by proteases in the endosomes formed by the 
endocytotic process. The insulin receptor   consists of four   subunits held   together 
by disulfide linkages. 6  Two alpha subunits that lie entirely outside the cell 
membrane and 2 betasubunits that   penetrate through the membrane, protruding   
into the cell cytoplasm. The insulin binds with alpha subunits on the outside of the 
cell; because   of the   linkages with the beta subunits the portions of the beta 
subunits protruding into the cell become   autophosphorylated. 
Binding of insulin   led to intrinsic tyrosine kinase activation; leads to 
receptor autophosphorylation and activation of intracellular- signaling molecules, 
insulin receptor substrates (IRS). Phosphorylation of cytoplasmic proteins and 
dephosphorylation reactions, promoted by IRS and adaptor proteins results various 
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metabolic effects like glycogen synthesis, protein synthesis, lipogenesis, and 
regulation of various genes in insulin-responsive cells.  
 
ACTIONS OF INSULIN: 
Immediate action consists of transport of glucose, amino acids, and 
potassium into insulin-sensitive cells. Intermediate action, within minutes include, 
inhibition of protein catabolism,   stimulation of glycolytic enzymes and glycogen 
synthase, inhibition of   phosphorylase    and   enzymes for   gluconeogenesis. 
Within hours it increase mRNAs for   lipogenic and other enzymes. 
 
EFFECT OF INSULIN ON VARIOUS TISSUES 
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General - Promotion of cell growth. 
 In Liver it reduce ketogenesis ,reduces glucose output due to decreased 
gluconeogenesis,  promotes glycogen  and    protein synthesis,    increased 
glycolysis and increased lipid synthesis. 
ADIPOSE TISSUE 
Insulin actions include glycerol phosphate synthesis, stimulation of 
triglyceride deposition, fatty acid synthesis, lipoprotein lipase enzyme activation, 
increased glucose entry into cells. Other actions includes   hormone-sensitive 
lipase inhibition7 and increased K+ uptake into cells. 
MUSCLE 
Insulin action includes   reduces protein catabolism,  increased potassium 
uptake, promote glucose entry into muscles, increased glycogen synthesis, 
decreased release of gluconeogenic amino acids,  ketone uptake into tissues  and 
increased protein synthesis  in  ribosomes8. 
Diabetes mellitus is a metabolic disorder characterized by chronic 
hyperglycemia along with abnormalities in carbohydrate, fat and protein 
metabolism due to deficiency in insulin secretion or action. 
AETIOLOGICAL CLASSIFICATION OF DIABETES 
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TYPE1-DIABETES 
Beta cell destruction leads to absolute insulin deficiency 
1. Autoimmune  
2. Idiopathic 
TYPE2 DIABETES 
1. Due to insulin resistance 
2. Insulin secretory defects 
3. Increased hepatic glucose production 
SPECIAL TYPES 
Genetic defect in beta cell dysfunction (MATURITY ONSET DIABETES OF 
YOUNG 1-6) 
Genetic defects insulin action 
1. Due to genetic disorders--like Klinefelter`s syndrome; Down’s syndrome, 
Turner’s syndrome; DIDMOAD; Friedreichs ataxia9 , myotonic dystrophy  
2. Endocrinedisorders (Acromegaly, Cushing’ssyndrome thyrotoxicosis             
glucagonoma;   phaeochromocytoma) 
3. Drug induced –steroids, diuretics -Thiazides 
4. Exocrine pancreas10 diseases like pancreatitis, neoplastic disease, cystic 
fibrosis, haemochromatosis, and pancreatectomy 
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5. Infections-virus like infection of rubella occurring via congenital 
transmission, mumps, coxsackievirus B 
 Immune-mediated diabetes due to other causes. 
 GESTATIONAL DIABETES. 
AETIOPATHOGENESIS OF TYPEI DIABETES 
TYPE1 DM Classified into type 1A, 1B 
TYPE I A --- ISLETS autoantibody positive, associated with GAD (GLUTAMIC 
ACID DECARBOXYLASE) DR3,DR4 
TYPE 1B ----autoantibody negative, genetics unknown 
1.) GENETIC FACTORS 
 Concordance of type1DM in identical twins---40%11 
 Polymorphism HLA complex located on chromosome 6 
 Most have HLA DR3, DR4Haplotype. 
 Chromosome 11 mutation insulin gene located. 
 Family history  
2.) ENVIRONMENTAL FACTORS 
Congenital rubella infection, entero viruses, rotavirus, parvovirus, 
coxsackie virus Toxin   rodenticide,   pentamidine 
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3.) Immunological factors-islet cell autoantibodies –different autoantibodies 
directed against islet cells includes 
 Eg:  GAD 65 ANTIBODIES,IA-2,ICA-512,ZNT-8 ;present in 85% of new onset 
type1DM 
PATHOPHYSIOLOGY 
 ISLET CELL AUTOANTIBODIES 
 ACTIVATED T LYMPHOCYTES 
 RELEASE OF CYTOKINES-TNF∞,INTERFERON,IF 1 
These factors leads to progressive destruction of beta cells leads to type 1 
diabetes. 
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RISK FACTORS OF TYPE 2 DIABETES 
Risk factors mainly includes genetic and environmental factors12 
It includes genetic factors, family history, demographic characteristics, age, 
sex ethnicity, lifestyle and behavioral- risk factors etc. Others are physical 
inactivity, stress, diet, obesity BMI> 25, hypertension BP>140/90, HDL 
Cholesterol<35mg/dL, polycystic ovarian syndrome etc. Impaired glucose 
tolerance, HbA1C 5.7_6.4%, insulin resistance, pregnancy-related determinants 
(parity, diabetes in offspring, H/O OF Gestational Diabetes Mellitus)13 are also 
included as risk factors. 
PATHOPHYSIOLOGY 
1) INSULIN RESISTANCE 
Reduced biological response to either exogenously administered insulin or 
endogenously produced insulin; which is influenced by genetic factors and 
obesity. Insulin resistance occur in various tissues liver, muscle splanchnic system 
etc. In type2 DM both receptor and post receptor defects (insulin regulated 
phosphorylation) leads to insulin resistance.  Post-binding defects are due to 
reduced production of insulin second messenger, decreased glucose transport into 
cell. In adipocytes which secrete various adipokines like leptin, free fatty acids, 
TNF, resistin, adiponectin, IL-6 these also influence insulin sensitivity. 
Adiponectin, insulin sensitizing peptide, decrease in obesity, cause increased 
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insulin resistance in liver. Free fatty acids reduce glucose uptake in skeletal 
muscle, increase glucose production in liver, and impairs beta cell function leads 
to insulin resistance. In muscles reduced receptor tyrosine kinase activity,   
reduced glucose transporters, reduced glycogen synthase play predominant role 
in resistance. Features of the insulin resistance syndrome includes 
hyperinsulinaemia type2diabetes, impaired glucose tolerance, 14  hypertension, 
low HDL cholesterol; elevated triglycerides, central obesity,    micro albuminuria 
etc 
2) IMPARIED INSULINSECRETION 
Insulin production initially increases to compete insulin resistance and to 
maintain plasma glucose level normal. Secretory impairment initially mild, 
progressively involves glucose mediated insulin secretion. Increased glucose 
levels have glucotoxicity effect, inhibits insulin release from beta cells. 
3) INCREASED HEPATIC GLUCOSE PRODUCTION 
Insulin resistance in liver leads to hyperglycemia, decreased glycogen   
storage, more hepatic glucose production 
4) INCRESED LIPIDSYNTHESIS 
In adipocytes increased free fatty acid synthesis and lipolysis leads to 
lipotoxicity, which induces   beta cell dysfunction. 
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DIABETES DIAGNOSING CRITERIA 
Normal glucose 
tolerance 
Impaired Fasting Glucose or 
Impaired Glucose Tolerance 
Diabetes mellitus 
Fasting Plasma 
Glucose<100 mg/dl 
Fasting plasma glucose 100-
125 mg/dl (IFG) 
Fasting Plasma 
Glucose ≥126 mg/dl 
2-hr PG <140 mg/Dl 2hour postprandial glucose 
140 -199 mg/dl (IGT) 
2 hour postprandial 
glucose ≥200 mg/dl 
 HbA1C <5.6%  5.7_6.4% >6.5%15 
 FPG fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired 
glucose tolerance; PG, plasma glucose 
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DIFFERENCE BETWEEN TYPE1 DIABETES AND TYPE2 DIABETES 
 
 Type1 Type2 
Typical age at onset years <40 >50 
Duration of symptoms Weeks Months to years 
Body weight         Normal Obese 
Autoantibodies Positive in 80% Negative 
Rapid death without 
treatment with insulin 
Yes No 
Family history  Uncommon Usually common 
Ketonuria Yes Nil 
Complications  
 
No More 
 
COMPLICATIONS OF DIABETES 
Diabetes has acute and chronic complications. Acute complications include 
diabetic ketoacidosis and hyperglycemic hyperosmolar state. Chronic 
complications of diabetes associated with more mortality of disease.it is classified 
into vascular and non-vascular complication. Chronic micro vascular   
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complications include diabetic neuropathy, nephropathy, and retinopathy. 
Macrovascular complications stroke, coronary artery heart disease, peripheral 
occlusive vascular disease 16 .Other non-vascular complications include gastro 
paresis, infections, sexual dysfunction, and periodontal disease. Retinopathy 
includes proliferative or non proliferative, macular edema, cataract etc. 
Neuropathy includes peripheral neuropathy, motor weakness, autonomic 
neuropathy etc. Cause of death in diabetes 70% mortality due to coronary artery 
disease17, 10% due to renal failure, 6% infections,10% cancer,1% DKA,5% others. 
Risk factors for more mortality in diabetes depends on duration of diabetes, micro 
albuminuria18, onset, obesity, associated hypertension, dyslipidemia, HbA1C etc. 
INFECTIONS 
Diabetic patients are susceptible to common infections 19 .  Inadequate 
glycemic control is a factor responsible for infections .Increase in blood glucose 
causes the growth and colonization of different organisms. Urinary infections, and 
soft tissue infections, lower respiratory infections occur in diabetes.  Patients with 
diabetes bacteriuria common. Urinary tract infections and pyelonephritis are 
caused by Escherichia coli, and Candida. Diabetic patients are prone to 
postoperative wound infections. 
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Diabetes are prone to furunculosis, superficial candida infections, and 
vulvovaginitis, skinfolds and nasal infection. Acute complications of diabetes 
include Diabetic ketoacidosis and hyperglycemic hyperosmolar state. 
INVESTIGATIONS OF DIABETES 
Blood glucose 
Urinalysis 
 Analyses for glucose, ketones, albumin (both macro- and micro 
albuminuria)  
 Macro albuminuria –urine albumin>300 mg/day.  
 Urine albumin creatinine ratio 2.5-30 mg/mmol if microalbuminuria 
present.  
Biochemistry include RBS, lipid profile and renal, liver and thyroid function. 
 Glycemic control assessment via Glycated hemoglobin (HbA1c) 
GLYCATED HAEMOGLOBIN (HBA1C) 
Objective measurement of diabetic glycemic control over a period of weeks 
to months is given. In diabetes; the slow non enzymatic covalent attachment of 
glucose to hemoglobin raises the amount in the HbA1c fraction. Because 
erythrocytes got life span of 120 days; HbA1c gives glycemic control over 2-3 
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months. These fractions can be separated by chromatography.The rate of 
formation of HbA1cs depending on blood glucose concentration; for 1% increase 
in HbA1C indicate average rise of blood glucose value 36 mg/dl. ADA 
recommends twice per year measurement of for optimal glycemic control. 
Anemia, hemoglobinopathies, reticulocytosis, blood transfusion will interfere with 
result.20 
MANAGEMENT OF DIABETES 
It includes assessment of patients   with history, clinical examination, and 
assessment of complications, investigation and medical management.   
History includes durations of diabetes, life style issues assessment like 
exercise, stress, smoking, alcohol,   and other comorbidities.  
Clinical examination   include body weight, body mass index, vitals and 
focus of infections etc. In diabetes target blood pressure should be less than 
140/90mm hg21. 
Assess for   dehydration– dry mouth, decreased tissue turgor if there is 
suspecting DKA. 
Eye examination should be done yearly .Foot examination   to assess 
peripheral pulses, sensation. 
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CNS examinations for patients with peripheral neuropathy, diabetic 
amyotrophy22.  
It includes sensory, motor   system examinations. 
Cardiac and renal evaluation yearly   for detecting complications 
Life   style modification which includes primary and secondary prevention. 
DIET control 
Hypocaloric diet that is low-fat or low-carbohydrate, high protein 
CARBOHYDRATE 45-50% 
FAT-<30% SATURATED<7% 
PROTEINS 20% 
Reduced trans-fatty acids, diet with low glycemic index is recommended. 
Exercise the ADA recommends 150 min/week of moderate exercise 
activity 23 .Exercise benefits includes lowering plasma glucose and increasing 
insulin sensitivity. Lifestyle optimization and education are essential for all 
patients with diabetes. Lifestyle modification designed for weight loss, including 
exercise medical and surgical interventions approved for   obesity, should be 
considered as primary approaches for therapeutic benefits in obese patients with 
diabetes, and for prevention of diabetes in high risk patients with   prediabetes.  
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Avoidance smoking, addictions 
TREATMENT OF ASSOSIATED CONDITIONS like- 
Hypertension, dyslipidemia, obesity, heart disease. 
MEDICAL MANAGEMENT OF TYPE 1 DM--Insulin administration 
MEDICAL MANAGEMENT TYPE 2DM 
Insulin, Oral anti diabetic drugs 
Antidiabetic drugs 
ORAL DRUGS 
 Biguanides 
Decrease hepatic glucose production, decrease gastrointestinal glucose 
absorption, and increase target cell insulin sensitivity 
Example: Metformin 
 INSULIN SECRETAGOGUES (increase insulin secretion) 
1) Sulfonylureas 
Examples: glyburide, glipizide, glimepiride, glibenclamide, tolbutamide 
2) Meglitinide derivatives (Non sulfonylureas) 
Eg. Repaglinide, nataglinide 
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3) Di peptidyl peptidase IV (DPP-4) inhibitors24 
Eg. Saxagliptin, sitagliptin, vildagliptin 
 Others included. 
 Alpha-glucosidase inhibitors—Decrease  GIT glucose absorption 
  Eg. Acarbose, Meglitol 
 Thiazolidinediones 25  (TZDs) –decrease insulin resistance, increased 
glucose utilization   
Eg ;  Rosiglitazones,  Pioglitazones 
 Selective sodium-glucose transporter-2 (SGLT-2) inhibitors reduce glucose 
reabsorption  
Eg: Dapagliflozin 
PARENTERAL DRUGS 
 Amylin agonists26 -slow gastric emptying, reduce glucagon eg. Pramlintide 
 Glucagonlike peptide–1 (GLP-1) agonists(parenteral preparations) 
Eg. Exenatide, liraglutide 
INSULIN PEPARATIONS 
SHORT ACTING- Aspart,   lispro, Regular, glulisine Duration of action 3-4 
HOURS 
Long acting --Detemir, glargine, NPH -Duration of action upto 24hrs 
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Combinations  
1. 75/25 --75% protamine lispro, 25%lispro 
2. 70/30 ---70% protamine,30% aspart 
3. 50/50—50% protamine,50% lispro 
4. 70/30 –70% NPH, 30% regular 
DIABETIC TREATMENT GOALS 
 Glycemic control - Pre-prandial capillary plasma glucose 70–130 mg/dl 
 Peak postprandial capillary plasma glucose<180 mg/dl  
 HB A1C should be less than7.0% 
 Blood pressure_--- less than130/80  
 LIPID PROFILE  
1. Triglycerides less than1.7 mmol/l (150 mg/dl) 
2. Low-density lipoprotein less than 100 mg/dl 
3. High-density lipoprotein--- 40 mg/dl 
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DIABETICKETOACIDOSIS 
Diabetic ketoacidosis is the most common and serious acute complication 
of diabetes. DKA usually occurs patients with type 1 DM, it can also occur in 
patients with type 2 DM. Type 2 DM patients with prolonged duration are more 
prone to DKA. Its incidence is   between 4 to 8.0 per 1000 diabetic patients.27 
DKA mostly precipitated by stressful conditions, such as infections, 
trauma. 
DKA consists ketonemia, hyperglycemia, acidemia. 
Hormonal imbalance leads to hepatic gluconeogenesis and glycogenolysis 
result in hyperglycemia.  Enhanced lipolysis leads to free fatty acids production 
that results increased ketone bodies, and metabolic acidosis. 
Symptoms include nausea, vomiting, increased thirst, polyuria, abdominal pain, 
breathlessness, altered sensorium etc. 
Physical findings 
 Fruity smell of breath 
 Tachycardia,Dehydration,Hypotension 
 Tachypnea, Kussmauls respirations28- rapid deep breathing 
 Abdominal tenderness  
 Lethargy, somnolence, coma,seizure 
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PRECIPITATING FACTORS FOR DKA 
1) Inadequate insulin, 
Insulin omission, 
Noncompliance to drugs, 
Insulin pump failure (20-40%), 
2) Infection 30-40% 
Sepsis 
Pneumonia, urinary tract infection, gastroenteritis 
3) Myocardial infarction29, stroke 6% 
4) Unrecognized symptoms of newly detected diabetes --8% 
5) Drugs. _10% 
Steroids, glucagon 
Diuretics, sympathomimmetics 
6) Alcohol 
7) Hypervolemia 
8) Non adherence to insulin treatment plans:   
Financial problems,  
9) Psychological factors 
10) Pregnancy 
11) Unknown 
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PATHOPHYSIOLOGY 
Normal metabolic homeostasis is maintained by balance between the 
anabolic action of insulin and catabolic effect of counter regulatory hormones. 
Diabetic ketoacidosis is caused by insulin deficiency with elevated 
counterregulatory hormone (glucagon, catecholamine, cortisol, and growth 
hormone). Insulin deficiency can leads to increased glucose production via 
glycogenolysis, gluconeogenesis, and ketone body and adipocytes formation in the 
liver, increases formation of free fatty acids. 
Defective insulin secretion and increased blood glucose levels decreases 
the hepatic fructose-2,6-bisphosphate, which changes the activity of 
phosphofructo kinase and fructose 1,6 bisphosphatase30 . Hyper glucogonemia 
reduces the action of pyruvate kinase and insulin deficiency increases the activity 
of phosphoenolpyruvatecarboxykinase. These leads to glucose synthesis from 
substrate pyruvate and   divert away from glycolysis. Insulin deficiency decreases 
glucose transport via reducing GLUT4 levels, which leads reduced glucose   intake 
into skeletal muscle and   which can reduces metabolism of glucose takes place 
inside cells. 
  Reduced insulin levels, and increased counter regulatory hormones, 
increase lipolysis and the release of free fatty acids.IN DKA, hyperglucagonemia 
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increase ketone body formation, through activation of the enzyme carnitine   
palmitoyltransferase I. This enzyme needed for fattyacid uptake into the 
mitochondria-where beta-oxidation and ketone bodies synthesis taken. Increased   
lactic acid synthesis lead to the acidosis. More free fatty acids lead to   triglyceride 
and VLDL production. 
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DIAGNOSTIC CRITERIA FOR DKA 
 Mild Moderate severe 
Arterial PH 7.24 to 
7.30 
7.00 to < 
7.24 
< 7.00 
Effective serum 
osmolality 
Variable Variable Variable 
Mental status Alert Alert/drowsy Stupor/coma 
Serum 
bicarbonate(meq/li) 
15 to 18  10 to 15 < 10 mEq /l 
Ketone (serum) Positive Positive Positive 
Urine ketone† Positive Positive Positive 
Anion gap (mEq/lit) > 10  > 12 mEq /li > 12 mEq /l 
Anion Gap = (serum Na + K) – (Cl- + HCO3-) ].  
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INVESTIGATIONS 
1) Blood Glucose-250–600 mg/dl 
2) Serum ketone level 7-10mmol/lit 
3) Serum potassium levels; it can be normal, high or low.  
4) In DKA if initial potassium values high, further treatment with insulin 
reduces potassium levels. 
5) Serum magnesium- measurement it can be low or normal  
6) Serum phosphate- normal or elevated 
7) Serum sodium - low or normal 
8) Serum chloride- Normal 
9) Serum osmolality_ more than 320 mOsm per kg  
10) Serum bicarbonate _< 15 mEq/L 
11) RFT--urea, creatinine level; It can be increased due to dehydration and    
reduced renal perfusion31 
12) Complete blood count   for infections, sepsis.   
13) ECG TO rule out MI or to find out electrolyte abnormalities. 
14) HbA1C LEVELS 
15) ARTERIAL BLOOD GAS  
Arterial blood gas measurement ---PH of arterial blood between 6.8 - 
7.3;  
Arterial PCO2 values20–30mmHg; 
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Aniongap_usuallymorethan15mEq/L        
16) URINE TEST for albumin, sugar, deposits and ketone should be done. 
17) Chest radiography can be taken if pneumonia or chronic obstructive 
pulmonary disease suspected. 
18) Serum amylase OR lipase can be done if suspected pancreatitis32 
19) Liver function test should be done in patients with alcoholism; and 
suspected fatty liver disease. 
20) Infection is suspected do urine and blood Cultures to identify organism. 
DIFFERENTIALDIAGNOSIS 
Hyperosmolar hyperglycemic state, Stress hyperglycemia 
Gastroenteritis, Pancreatitis 
Ketosis due to starvation, lactic acidosis, Hyperchloremic acidosis 
Salicylate poisoning; uremic acidosis 
High Aniongap metabolic acidosis present in alcoholic ketosis, ethylene 
glycol poisoning 
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HYPERGLYCEMIC HYPEROSMOLAR STATE 
HHS consists of hyperglycemia, hyperosmolarity, severe dehydration and 
neurological manifestations like lethargy, coma 33 .It can be precipitated by 
infections, trauma, immunosuppressive agents, drugs like steroids, alcoholism 
stroke etc. It can be prolonged over weeks with presenting symptoms of polyuria, 
polydipsia, weight loss, confusion, and coma. 
Investigations for patients with hyperosmolar hyperglycemic patients 
INVESTIGATIONS HHS 
GLUCOSE 600-1200mg/dl 
SODIUM 135-145meq/l 
POTASSIUM,CHLORIDE,MAGNESIUM Normal 
PLASMA KETONES +/_ 
S BICARBONATE Normal 
OSMOLARITY 330-380mosm/ml 
ARTERIAL PH 7.3 
ARTERIAL PCO2 Normal 
ANION GAP Normal 
Creatinine Increased 
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Management of HHS consists of fluids replacement, correction of 
precipitating factors, correction of osmolarity, low dose insulin and correction of 
electrolytes. 
TREATMENT OF DKA 
 It includes adequate fluid replacement, insulin infusion, correction of 
hyperglycemia and electrolyte abnormalities. 
 Initial assessment to determine severity of acidosis include the following .If 
one or more factors present then consider severe DKA. 
It includes 
 Pulse   high 100 or below 60   per minute 
 Serum bicarbonate (HCO3) levels   lessthan5mmol/l 
 SPO2 below 92% on air  
 Systolic BP below 90 mmHg 
 PH OF arterial blood<7.1 
 Blood ketones over 6 mmol/L 
 Glasgow coma scale less than 12 
 Anion gap above 16. 
New principles in treatment of DKA 
  According to weight of patient, insulin infusion rate is calculated.  Insulin   
dose adjustment; calculated via body weight allows insulin resistant states to be 
accommodated. . If blood ketone measurements are available the response of the 
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insulin regimen is determined by the rate of reduction of the ketones and can do 
dose adjustment if this is inadequate. During the first 6 hours, the bicarbonate level 
can be used for assessment but may be less reliable thereafter.  It can be used only 
when glucose levels are relatively normal.  Start a fixed rate insulin infusion only 
after initiation of fluid therapy34. 
Establish monitoring regime appropriate to patient; generally hourly blood 
glucose and ketone measurement; with at least 2 hourly potassium levels for the 
first six hours to be needed. 
Initial management  
 Assessment Airway, Breathing, Circulation. 
 Then insert   iv cannulae and start of iv fluids. 
 Check vitals   respiratory rate, blood pressure, pulse, temperature 
 Respiratory rate; patient can have rapid deep breathing 
 Temperature high   in the presence of sepsis or infection 
 Blood pressure it can be hypotension or normal 
 Pulse   tachycardia in sepsis, infection 
 Oxygen saturation 
 Insertion of nasogastric tube   for airway protection  
 Do clinical examination   including system examination for identifying 
complications. 
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 Initial blood tests should be done as mentioned above, do monitoring of 
cardiac activity, SPO2 monitoring .Search for causes of DKA and treat  
causes. 
FLUID REPLACEMENT 
Immediate management 
First one hours 
Start intravenous fluids. Total water deficit for patients   with DKA is 
approximately 7% to9% weight of the body35. Hypotension   occurs due to a loss 
of morethan 10 percentage of body fluids. Initially, correction of dehydration using 
isotonic 0.9%saline can be given. The first liter can be given with in half hours 
and   followed by iv fluids at a rate of 1L/hr; till the volume deficit is corrected. If 
systolic BP<90 mmHg give 500ml 0.9% normal saline over 10-15 min. then 
reassess ,if  blood pressure remains <90mmHg seek senior review 
.Hypotonic(0.45%) saline solution considered for severe hypernatremia; serum 
sodium >155 mEq/L. If no improvement search other causes of hypotension treat 
it. 
Systolic BP on admission >90 mmHg give0.9%normal saline 1lit over 60 min 
THE NEXT step - REPLENISH TOTAL BODY WATER DEFICITS; 
0.9%  normal saline at a 150 to 500ml/hour rate is appropriate serum 
sodium is  normal; Assess cardiac and renal status ,the degree of dehydration for 
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calculating  rate of the fluid replacement  Assessment of fluids replacement  done 
by improvement in blood pressure, measurement of fluid balance, and clinical 
examination. IN a typical DKA patient   complete fluid replacement take12 to24 
hours. 
INTRA-VENOUS INSULIN INFUSION 
Initial bolus dose of regular insulin 0.1 unit/kg can be given;   followed by 
rate of 0.1unit/kg/hour insulin infusion can be given.  
Start continuous fixed rate via an infusion pump. 50units human soluble 
insulin diluted in 50ml with 0.9%sodium chloride solution give via infusion pump. 
  Regular insulin;   50units in 500 mL 0.9% saline, infused at a rate of 5 units 
per hour of insulin can be started. 
 Reduction in glucose level of 50 --75 mg/dl/hour is an adequate response36; 
Insulin   can increase progressively by 50 to100% until an adequate glycemic 
response     is   obtained. Increase intravenous insulin by 50% if blood glucose 
change <50mg/dl/hr. Decrease   insulin infusion by 50% if blood glucose decreases 
by >100 mg/dl/hr in any   one hour. 
 Maintenance insulin infusion rates of 1 to2 units or higher and the anion 
gap has closed .When blood glucose reaches lessthan 250 mg/dl add 5%dextrose37 
to IV fluids. If the patient started to take oral feeds or sensorium becomes 
improved change insulin to subcutaneous route and the parenteral route can be 
stopped. Before stopping the   intravenous insulin, give the first SC   dose of insulin 
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injection. Rapid correction of glucose levels at a rate >100 mg/dl can cause 
osmotic encephalopathy. 
Monitoring regime include generally hourly blood glucose measurement, 
ketone measurement, with at least 2 hourly potassium and other electrolytes for 
the first six hours. Potassium is often high but falls   rapidly with insulin infusion. 
Regular monitoring is mandatory 
MANAGEMENT 60 minutes to 12 hours 
  Give 0.9% sodium chloride  1000ml over  first hour; followed by  0.9% 
sodium chloride 1Litres over next 2 hours.Repeat0.9% sodium chloride 1Litres 
over next 2 hours .Next 4 hours give  1000ml normal saline slowly. Repeat 1litres 
over next 4 hours. Then give 0.9% sodium chloride 1L1000ml over next 6 hours. 
Add potassium chloride to this solution if indicated 
Adjust KCL Infusion 
Plasma potassium(mmol/l) Potassium needed(mmol per litre of 
infusion) 
>5.5 Not needed 
 between3.5-- 5.5 40mmol/lit  
<3.5 Additional potassium 
 
Assessment of cardiac status at 12 hours should be done. Patients with heart 
disease/ renal failure, elderly, pregnant patients need monitoring for fluid 
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replacement. Fluids should be replaced   under caution; monitored via the central 
venous pressure measurements. 
Average loss of fluid and electrolytes in adult diabetic ketoacidosis  
Water- 6litres; Sodium: 500 mmol  ;   Chloride-400 mmol    Potassium: 350 mmol 
3L extra cellular38 can be replaced with saline; 3L intracellular   replace with 
dextrose   commence a fixed rate12 -24 hours.  
Ketonemia and acidosis should have resolved. Adequate ketone reduction 
is 0.5mmol/L/hr. If it is not available; HCO3 should rise by 3mmol/litre/hour and 
blood glucose should fall by 3 mmol/litres/hour. 
If patient is not taking oral feeds continue iv insulin infusion at a lower rate 
of 2-3u/hour and continue iv fluid replacement. 
If ketoacidosis resolved patient taking oral feeds then change to 
subcutaneous insulin. 
BICARBONATE REPLACEMENT IF PH>7 no bicarbonate needed, if it is<6.9 
give   100mmol sodium bicarbonate in 400ml saline at a rate of 200ml/hour 
infusion. 
ADDITIONAL PROCEDURES 
Insertion of urinary catheter if   reduction in   urine output. 
 Insertion of Ryle’s tube if patient persistently vomiting or having altered 
sensorium. Oxygen administration   -SPO2<80MmHg. 
Repeat chest radiography.  
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Maintain intake/output chart, minimum urine output should be 0.5ml/kg/hr.  
Cardiac monitoring should be done; if DKA is severe. 
Serious complications of DKA and its treatment  
1) HYPONATREMIA can be corrected by 3% hypertonic saline. 
2) HYPOKALAEMIA AND HYPERKALAEMIA 
Hypokalemia and hyperkalemia are potentially life threatening conditions 
in the management of DKA39. Due to increased risk of acute prerenal failure 
associated with severe dehydration and it is therefore recommended that no 
potassium needed if the serum potassium level remains above 5.5 mmol/L. If the 
serum potassium level falls below     3.5mmol/l the potassium regimen needs 
review.  
3) HYPOGLYCAEMIA 
Severe hypoglycemia can cause cardiac arrhythmias, acute brain injury and 
death. Rapid blood glucose   reduction can   cause rebound ketoacidosis. Once the 
blood glucose falls to 14mmol/L give 10% dextrose. 
4) CEREBRAL EDEMA40  
Observed more in children than adults. Patients with cerebral edema can 
have symptoms of raised intra cranial pressure like sudden deterioration in mental 
status, headache, altered mental status, papilledema edema. Treatment   includes 
IV mannitol, oral glycerol, head end elevation, hyperventilation .CT BRAIN can 
establish the diagnosis.  
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5) Metabolic acidosis and Lactic acidosis - Adequate volume replacement, and 
correction of bicarbonate, sepsis control will improve acidosis. 
6) Acute renal failure  
7) Aspirationpneumonitis 
8) Pulmonaryedema  
9) Adult   respiratorydistress syndrome 
10) disseminated intravascular coagulation, basilar artery thrombosis 
11) Venous thrombosis and Arterial thrombosis  
12) Pneumothorax, pneumomediastinum and subcutaneous emphysema  
13) Rhabdomyolysis. 
Prevention of DKA. 
DKA occur due to lack of clinical communication41.Insulin omission can 
be prevented by medical education, psychosocial   assessment and treatment   
along with supervision of insulin administration. Educate patients with   what are 
risk factors, symptoms of   DKA so they can identify DKA of early onset.  
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MATERIALS AND METHODS 
This study was an observational cross sectional study conducted in 
Tirunelveli Medical College, Department of   Medicine, during the period from of 
August 2014 to August 2015. The aim was to study the symptomatology,   risk 
factors and prognosis of Diabetic ketoacidosis. The necessary clearances from the 
concerned departments and the ethical committee was obtained prior to the start 
of the study. 
 All patients admitted to the Intensive   medical Care Unit in whom a 
diagnosis of DKA was made based on clinical features, with diabetes and elevated 
random blood sugar, urine acetone positive were considered for the study. Patients 
were included in the study based on inclusion and exclusion criteria. 
INCLUSION CRITERIA 
1) Patients with type1, and type2 diabetes with high blood sugar, urine acetone 
positive 
2) All type2 diabetic patients under stressful conditions like stroke, MI, sepsis 
3) Patients with high blood sugar values on irregular medication 
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EXCLUSION CRITERIA 
Terminally ill patients (more than one comorbidities). 
Sepsis is identified by SIRS 42    criteria with pulse rate, temperature, 
respiratory rate. Blood culture and urine culture was done to identifying 
organisms. 
An oral consent was taken from all patients for a detailed clinical history 
and examination and the required laboratory   investigations. The details were 
collected from each patient was entered in the proforma. (Annexure-1). 
The details of the patients regarding age, sex, presenting   symptoms,   risk 
factors like non-compliance, infections, other drugs were recorded. The vital signs 
like pulse and blood pressure, respiratory rate, temperature were recorded and 
Body mass index was calculated. All the patients were subjected to routine 
laboratory investigations like CBC, urine analysis, urine ketones, RBS, RFT, 
electrolytes. Arterial blood gas analysis was done for acidosis. Blood culture, urine 
culture was   done for those patients with sepsis. Chest X- ray, ECG, USG   
abdomen was done according to patient symptoms. Continuous monitoring of 
RBS, electrolytes   was done. Patient was treated with adequate IV fluids, and 
insulin infusion. Precipitating factors was identified and treated. 
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URINE ACETONE done by ROTHERA´S TEST43 
PRINCIPLE - Nitroprusside in alkaline medium reacts with    a ketone group to 
form a purple ring. It is given by acetone and acetoacetone, but not by Beta 
hydroxyl butyric acid. On boiling   acetoacetate is converted   to acetone and does 
not give this test positive. 
PROCEDURE 
Saturate 5 ml of   urine with solid ammonium sulphate and add 0.5 ml of 
freshly prepared   sodiumnitroprusside 5%. Mix well and add liquor ammonia   
from side of tube. A purple ring at the junction of   liquids indicates   the presence 
of ketone bodies. 
ARTERIAL BLOOD GAS ANALYSIS 
Procedure-Site-blood can be taken from arteries like radial artery/femoral 
artery and brachial artery. Pre heparinized syringes needed44-- Syringes flushed 
with 0.5ml of 1:1000 Heparin solution and emptied. More than 50% blood needed; 
ensure no air bubbles with in the syringe.  Syringe   should be transported as soon 
as to the laboratory for early   interpretation via cold chain. 
Principle of ABG   Henderson---Hasselbalch equation45 
pH value=6.1+log[
𝐻𝐶𝑂3−
0.03𝑋𝑃𝐶𝑂2
] 
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NORMAL VALUES OF ABG 
 pH values between 7.35 to 7.45;pCO2  between 35 to45  mmHg, pO2  
between 72to104 mmHg, bicarbonate values between 22 to 30 mEq/l anion gap   
ranges from 8to16 mEq/l. ANION GAP= (Na+k )– (HCO3+ Chloride) mEq/l    
INTERPRETATION 
 pH Less than 7.35 acidosis; more than 7.45 alkalosis 
 If pH and pCO2 decreases   or pH and pCO2 increases in the same 
direction,it should be metabolic. 
 If pH and pCO2 changes in the opposite direction it should be respiratory 
METABOLIC ACIDOSIS pCO2=1.5x(HCO3)+8±2 
For every 1 mmol/l decrease in HCO3   pCO2 falls by 1.25 mmHg 
METABOLIC ALKALOSIS --for every 1 mmol/l rise in HCO3   pCO2 should 
be increased by 0.7 mmHg46.In metabolic acidosis anion gap should be calculated 
Statistical analysis 
 The information collected regarding all the selected cases were recorded in 
a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for Disease 
Control, Atlanta, USA 
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OBSERVATION AND RESULTS 
100 patients admitted with clinical features, raised blood sugar values, urine 
acetone positive were selected. 
1) SEX DISTRIBUTION(table1) 
Sex 
Cases 
No % 
Male 58 58 
Female 42 42 
Total 100 100 
 
Figure 1 MALE TO FEMALE RATIO. Among 100 patients 58 males and 
42 females, so males were commonly affected. 
 
Male, 58
Female, 42
Male to Female Ratio
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2) RATIO OF TYPE I TO TYPE2 DIABETES IN DKA(table2) 
Among 100 patients 30 had type 1 diabetes, 70 had type2 diabetes. 9   patients 
were new onset diabetes. New onset type 2 were 8 patients, 1 patient  had new 
onset type1. 
TYPE OF 
DIABETES(INCLUDING 
NEW ONSET) 
NO OF 
CASES 
PERCENTAGE 
TYPE 1 30 30% 
TYPE2 70 70% 
TOTAL 100 100 
 
 
FIGURE 2  RATIO OF TYPE 1 TO TYPE2 
  
Type1
30%
TYPE2
70%
Ratio of Type 1 to Type 2 Diabetes in DKA
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3) AGE DISTRIBUTION(TABLE3) 
Age No % 
Upto 40 years 30 30 
41 – 50 years 11 11 
51 – 60 years 29 29 
61 – 70 years 19 19 
Above 70 years 11 11 
Total  100 100 
Younger group 30 30 
Older group 70 70 
Range 14-82yrs 
Mean 47.2  yrs 
 
 
 
 
30%, 30%
70%, 70%
upto40 yrs above40
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FIGURE 3) AGE DISTRIBUTION 
In the study the youngest patient was a 14 year old male and the oldest 
patient was a 82 year old male.30 cases were younger than 40 years, mostly type 
1 patients. 70 cases   were above 40 years with type2 patients. The mean age group 
was 47.2 years. Among type 2 diabetes patients   DKA mostly seen among age 
between 51-60 yrs. 
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4. PRESENTING SYMPTOMS(TABLE4) 
 
 
 
 
 
 
figure4 –SYMPTOMS 
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30.00
30.00
37.00 38.00
Symptoms
symptoms NO OF CASES 
vomiting 30 
fever 30 
altered sensorium 37 
foci of infection 38 
total 100* 
*Some had multiple symptoms.  
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Symptoms includes fever, altered sensorium47, vomiting, foci of infections 
like, soft tissues infection, dysuria, cough, loose stools. Among that 38% had focus 
of infection like symptoms. 37 patients   had altered sensorium, 30 patients had 
fever as symptom              
5. TYPES OF FOCUS OF INFECTION(table5) 
In this study 38% had symptoms like focus of infection. Among that 13% 
have urinary tract infection, 10% had soft tissue infections,7% had lower 
respiratory tract infections.8%   had acute diarrheal illness. 
Focus of infection No of cases 
Urinary tract infection 13 
LRI 7 
Soft tissue infections 10 
Acute gastroenteritis/ADD 8 
total 38 
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FIGURE 5- TYPE OF INFECTIONS 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
13
7
10
8
TYPE OF INFECTIONS
ADD/Accute Gastroentritis
Soft Tissue
Lower Respiratory Infection
Urinary Tract Infection
 
 
 
 
53 
 
6. TREATMENT TAKEN (table6) 
 
 
*some patient were 
on insulin and oral 
drugs 
 
FIGURE 6 TYPE OF TREATMENT 
 
Among 70 patients with type2 diabetes 49 were taking oral anti diabetic 
drugs , both insulin and Oral drugs taken  by 15patients . 30 type1 patients   were  
insulin only. New onset diabetes treatment cannot assessed. 
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Treatment Taken
TYPE OF TREATMENT NO OF PATIENTS 
INSULIN 31 
BOTH 15 
Oral antidiabetic drugs 49 
total 100* 
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7. TREATMENT COMPLIANCE (table7) 
Among diabetes patients most of them were not on treatment regularly. In 
this study 48% DKA patients were not taking treatment regularly. Diabetes of 
newonset included in compliance. 
TREATMENT 
COMPLIANCE 
 NO OF PATIENTS 
COMPLIANCE 52 
NONCOMPLIANCE 48 
TOTAL 100* 
 
FIGURE 7 COMPLIANCE VS NONCOMPLIANCE 
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8. ASSOCIATED COMORBIDITIES (table8) 
ASSOSIATED 
COMORBIDITIES 
NO OF PATIENTS 
coronary artery disease 12 
chronic kidney disease 9 
COPD 10 
Stroke(CVA) 7 
HYPERTENSION 2 
total 40 
     
                                             FIGURE8 ASSOSIATEDCOMORBIDITIES  
CAD-12%,CVA7%,HYPERTENSION2%,CKD9%,COPD10%.Patients 
with more than one comorbidities not included. 
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9. DURATION OF DIABETES (table9) 
Duration of Diabetes NO OF CASES 
<5YEARS 58 
5-9 YEARS 32 
≥10 Years 10 
TOTAL 100 
Figure 9 DURATION OF DIABETES 
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In this study 58% had diabetes of less than 5 years duration,32% had 5to9 
years duration;10% had  diabetes of more than 10 years . New patients were 
included in <5 yrs. 
 
10. PRECIPITATING FACTORS OF DKA(table10) 
Risk factors no of cases 
non compliance 48 
infections 38 
sepsis 14 
steroids 10 
myocardial infarction 5 
stroke 3 
alcoholic  8 
 100* 
*One patient had more than one precipitating factors 
 In this study   DKA had multiple precipitating factors like noncompliance, 
infections, sepsis48, MI, stroke, alcoholism. Among that 48% had noncompliance, 
38 patients had infections, 14 had sepsis, and 10 patients were on steroids. 5 
patients had acute stressful condition like MI, 3 had stroke. Overall precipitating 
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factors had p value <0.001; so each precipitating factors had significant association 
with DKA. 
 
 
Figure 10 -PRECIPITATING FACTORS 
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11. BODY MASS INDEX(table11) 
BMI Cases 
<18 4 4% 
18-25 (Normal) 66 66% 
25-30 (Over-Weight) 25 25% 
30-35 (Obese I) 5 5% 
35-40 (Obese II) 0 0% 
Total 100 100% 
Range 16.7-32.1 
Mean 23.2 
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Figure 11 BMI 
66% -normal BMI ,25% overweight category,5%  obese I category. The 
mean body mass index around 23.2 
12. VITALS(table12) 
Pulse rate ranged from 68-108; mean 87.29. Respiratory rate ranged between 
14-28 mean values 18.6. 
 Range Mean SD 
Pulse rate 68-108 87.29 7.46 
RESPIRATORY 
RATE 
14-28 18.6 2.89 
 
<18 (Mal-
nutrition), 4
18-25 (Normal), 
66
25-30 (Over-
Weight), 25
>30 (Obese), 5
BMI
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Figure12) VITALS 
 
 
13. BLOOD SUGAR, UREA & CREATININE LEVELS(table13) 
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VARIABLES Range Mean SD 
Blood Sugar(mg/dl 380-659 523.22 62.19 
Urea(mg/dl) 34-94 50.42 13.24 
 
Creatinine(mg/dl) 
0.8-3.9 1.612 0.56 
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Figure 13 VARIABLES- BLOOD SUGAR, UREA, and CREATININE 
The average blood sugar value was 523.22 mg% with a ranged between 380 
mg %and 659 mg%. The mean urea values were 50.42 mg%. The average 
creatinine values were 1.612...Standard deviation (SD) was calculated. 
14. ELECTROLYTE AND PH,BICARBONATE 
LEVELS(table14) 
Variable Range Mean SD 
POTASSIUM 
(K)mEq/l 
2.8-6.2 4.33 0.734 
SODIUM(Na)mEq/l 124-136 133.24 2.86 
pH 6.02-7.30 7.13 0.31 
Mean
SD
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BICARBONATEmEq/l 6-17 12.56 2.69 
Figure 14 VARIABLES –POTASSIUM, SODIUM, BICARBONATE, PH 
Average potassium value 4.33,ranged  between 2.8to 6.2.Sodium  levels 
ranges between 124to 136 meq/l. Average value of serum sodium 133.24..ABG 
;PH Value ranged between 6.02 to7.30,mean pH 7.13.Bicarbonate  ranged 
between6 to17;mean bicarbonate 12.56. 
 
15. COMPLICATIONS(table15) 
Complications No of cases 
Death 16 
Prolonged hospital stay>2week 25 
Mean
Standard Deviation0
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2.69
 
 
 
 
64 
 
Sepsis 14 
Electrolyte  abnormalities 32 
Respiratory failure 16 
Severe acidosis 8 
Altered sensorium with  
encephalopathy 
14 
Total 100* 
*One patient can have more than one complications 
DKA had many complications.IN this study among 100 patients most of 
patients had more than one complication.16 patients died due to various 
complications. 
Morbidity assessed by prolonged hospital stay>2week duration with 
various complications.26 patients had prolonged hospital stay. Electrolyte 
disturbances 49  like hypokalemia, hyponatremia, hyperkalemia were occurred 
among 32 patients. Respiratory failure were seen in 16 patients.14 patients had 
developed altered sensorium, metabolic encephalopathy.14 patients had 
developed severe sepsis 
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Figure 15 COMPLICATIONS 
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16. ELECTROLYTE ABNORMALITIES (table16). 
Electrolyte No of patients 
hyperkalemia 4 
Hyponatremia 11 
hypokalemia 17 
 
 
Figure 16 ELECTROLYTE ABNORMALITIES. 
Among 100 patients,17 patients had developed hypokalemia,4had 
hyperkalemia,11 patients had developed  hyponatremia. 
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17. RELATION BETWEEN TYPE OF TREATMENT TAKEN 
WITH MORTALITY AND MORBIDITY(table17) 
Treatment type Death <2 Weeks >2week* total 
oralantidiabetic 
drugs 
11 22 16 49 
Insulin 1 24 6 31 
Both 4 7 4 15 
total 16 53 26 100* 
* some patient were on insulin and oral diabetic drugs ; some patients  new onset 
DM
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Figure 17 relation between type of treatment and outcomes 
In this study patients with oral antidiabetic drugs had high mortality and 
morbidity (which was determined by prolonged hospital stay>2week and 
complications). Among total 16 deaths 11 patients were on oral diabetic drugs.  
Patients those were on both   insulin and oral drugs 4deaths were observed.  
Patients with only insulin 1 death was observed.16 patients with OHA had 
prolonged hospital stay and complications.  4patients taken both had prolonged 
hospital stay.6 patients   taken only insulin had prolonged hospital stay. Patients 
those taken oral hypoglycemic drugs had more mortality compared to insulin; p 
value was <0.001 statistically significant. 
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18. SEVERITY OF ACIDOSIS BASED PH VALUE; AND ITS 
ASSOCIATION WITH MORTALITY (table18). 
type of acidosis  No of patients Death % 
mild (pH>7.25 35 2 5.7% 
moderate(pH 7 
to7.25 
57 10 17.5% 
severe( pH<7) 8 4 50% 
total  100   
Range  6.02-7.3 
 
Mean  ----7.13 
Figure 18 -severity of acidosis 
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Based on PH value patients were classified into mild, moderate, severe 
acidosis .PH<7   with severe acidosis observed in 8 patients.57 patients had pH 
ranged 7 to7.25 grouped into moderate acidosis.PH value >7.25 with mild acidosis 
were 35 patients. PH value ranged from 6.02 to 7.30. Moderate to severe acidosis 
can cause more mortality and morbidity.  8 patients with severe acidosis, 4 death 
were observed. Patients with moderate acidosis 10 death were occurred. So there 
is a significant association between mortality with severity of acidosis,   p 
value<0.001 was statistically significant. 
19. RELATION OF MICROALBUMINURIA  WITH 
MORTALITY AND MORBIDITY(table19) 
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mild(PH (>7.25) moderate(pH 7-7.25) severe(ph<7)
35
57
8
severity of acidosis
 
 
 
 
71 
 
Outcomes NO OF PATIENTS 
DEATH (16) 9 
>2WEEK*(26) 13 
<2WEEK 6 
TOTAL 28 
*>2 WEEK INDICATES MORBIDITY 
Figure 19 relation of microalbuminuria with mortality and morbidity 
 
Microalbuminuria observed in association with morbidity and mortality.28 
patients had microalbuminuria; among 16death 9Patients had microalbuminuria, 
patients with hospital stay>2 week 13 had micro albuminuria. 
20.  RELATION BETWEEN BLOOD SUGAR VALUES WITH 
MORTALITYAND MORBIDITY (TABLE20) 
0
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RBS(mg/dl) DEATH >2WEEK TOTAL 
<400mg/dl 0 1 1 
400-500 1 7 8 
500-600 10 15 25 
>600 5 2 7 
Figure 20 RELATION OF BLOOD SUGAR WITH OUTCOMES 
 
Among patients with DKA blood sugar values ranged from 380-659mg/dl. 
Mortality increased with high RBS value .More death   were observed when   RBS 
DEATH
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15
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value >500mg/dl.10death were observed with RBS   range 500-600.In this RBS 
range- prolonged hospital stay were observed in15 patients.5 death were occurred 
when RBS morethan600mg/dl. Below 500mg/dl; one death was observed. So 
higher the blood sugar values more mortality and morbidity; p value< 0.001 was 
statistically significant 
 
 
 
 
 
 
 
 
 
 
21. RELATION BETEEN MORTALITY AND ASSOSIATED  
COMORBIDITIES.(TABLE21). 
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RISK FACTORS Death 
CAD 5 
CVA 1 
CKD 3 
COPD 0 
SEPSIS 7 
TOTAL 16 
 
Figure. 21 RELATION BETWEEN MORTALITY AND ASSOSIATED 
COMORBIDITIES 
Among 16 deaths most of them had associated with other comorbid 
illness.5 patients   had suffered coronary artery disease. Severe sepsis observed 
among 7 patients.3 patients had chronic kidney disease 
0
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22. RELATION BETWEEN DIABETES DURATION & 
MORTALITY AND MORBIDITY(TABLE22). 
 Death <2 Weeks >2WEEKS 
<5Years 3 44 11 
5 -9years 7 14 11 
≥10Years  6 1 3 
TOTAL 16 59 25 
.  New onset diabetes also included in less than 5yr 
 
 
Figure 22 RELATION BETWEEN DURATION OF DM AND DEATH 
RELATION OF DURATION OF DIABETES 
AND DEATH
<5YRS
5-9 YRS
>10
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Figure 23 RELATION BETWEEN DURATION AND OUTCOMES
 
Among 58 patients with <5 years diabetes duration 3 deaths; 11 patients 
had prolonged hospital stay observed. Among 32 patients with diabetes 5 to 9yrs 
7 deaths; 11 patients had prolonged hospital stay due to complications observed. 
Out of 10 patients with diabetes more than 10 years 6 deaths occurred; 3 patients 
had prolonged hospital stay observed. So duration of diabetes had significant 
relation between DKA mortality and morbidity50 p value< 0.001; was statistically 
significant. 
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DISCUSSION 
Diabetic keto acidosis is a serious acute complication of diabetes. 
DKA--- a hyperglycemic emergency   which is an important   cause of 
morbidity and mortality in patients with diabetes.  This study has been done with 
regard to risk factors in the predominantly rural population. 
DKA is common among Type 1 diabetes patients; may be a first presenting 
feature of type1 DM. In Type 2 diabetes patients with prolonged duration; can 
develop DKA  in conditions, such as  infections51,sepsis   and stressful situations  
like myocardial infarction, stroke .Most important precipitating factors include 
noncompliance  to drugs or insulin omission. 
In this study male   to female ratio 58:42. DKA was most commonly seen 
among males. Among 58 males; 16 had type 1 diabetes, 42 had type 2 diabetes. 
Among 42 females; 14 had type 1 diabetes, 18 had type 2 diabetes. In this study 
DKA were more common among males.70 patients had type 2 diabetes; 30 
patients had type 1 diabetes. Among 100 patients 9% patients (9 cases) had new 
onset of diabetes presented as DKA. 
In this study among Type 2 DM patients DKA were common between 50-
60yrs. In our study among type 2DM cases 59%were below 70 years. Type 1 DM 
DKA were common between 14 -23 yrs. 
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Most of patients had more than one symptoms. Common symptoms include 
fever, vomiting, altered sensorium, specific symptoms for infections like urinary 
tract infections52, lower respiratory infections. Most of the patients had more than 
one symptom. With regarding to presenting complaint 38% had symptoms specific 
to focus of infection like dysuria, cough, loose stools, no healing ulcers and 37 
patients had altered sensorium, 30 patients had fever as presenting symptom 
.Among  the focus of infections13 had symptoms urinary tract infection,7 had 
lower respiratory tract infections53 ,10patients were suffered from soft  tissue 
infections. 8 had acute gastroenteritis/acute diarrheal   disease. Diabetes were more 
prone for common infections like urinary tract infections and soft tissue infections. 
Patients with uncontrolled hyperglycemia were more prone for infections. In 
Nigerian study by Andrew about DKA common symptoms observed; fever, 
altered sensorium, breathlessness etc. 
Among 70 patients with type2 diabetes 49patients  were on oral anti 
diabetic drugs , 15patients were on insulin and oral antidiabetic drugs .Among 30 
type1 patients  all  were taking insulin only.  Among diabetes patients most of 
them not taking treatment regularly .In this study 48% DKA patients were   not on 
regular treatment. 
In any acute stressful conditions like infections, sepsis, MI; omission of 
insulin54 cause DKA. In this study the predominant precipitating factors were 
related to insulin therapy (missed insulin injection, change in insulin dose or 
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regimen), noncompliance and infections. In this study drug noncompliance (48%) 
was most common precipitating factor for DKA. Many patients had more than one 
risk factors. Among 100 patients; 38 had infections, 14 had sepsis, 10 patients were 
on steroids.  Acute stressful condition like MI55, stroke   were precipitating factors 
among 8% patients. Among alcoholics 8% patients with irregular treatment led to 
DKA. Noncompliance in rural population was due to low socioeconomic status 
and lack of knowledge .Most of the diabetic patients had no proper follow up; and 
also unaware of complications. 
Many of the patients had more than one risk factors. Overall pvalue<0.001 
for risk factors, so was statistically significant. In a similar study done in New 
jersey56, most important precipitating factors were related to drug therapy, insulin 
omission. 
In a Nigerian study by Andrew and American study 57 by John; most 
significant risk factor mentioned were non-compliance and infections. In Nigerian 
study malarial infections   was included as a risk factor; it was not found in this 
study. 
DKA had various complications like electrolyte abnormalities, sepsis, respiratory 
failure, severe acidosis. DKA is an important cause of mortality in diabetes 
patients. In this study among 100 patients most of patients had more than one 
complication.16 patients were died due to various complications. Morbidity 
assessed by prolonged hospital stay>2week duration with various 
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complications.26 patients had prolonged hospital stay. Electrolyte disturbances 
like hypokalemia, hyponatremia, hyperkalemia were occurred among 32 patients. 
Respiratory failure 58  were occurred in16 patients.14 patients had developed 
altered sensorium due to metabolic encephalopathy.14 patients had developed 
severe sepsis. In a study conducted in Nigeria59 by Andrew, hyponatremia and 
hyperkalemia, hypokalemia were commonly observed. .In a similar study done in 
Israel 60 , complications observed   were death, respiratory failure, multiorgan 
failure, electrolyte abnormalities, acidosis, altered sensorium etc. Association of 
comorbidities also mentioned in that study. 
Most of the diabetic patients had chronic complications like CKD, 
STROKE, and CAD. In our study, comorbidities like coronary artery disease was 
found in 12% of the cases and chronic kidney disease in 9% patients stroke in 7% 
cases, 2% hypertension 10% patient had COPD. Associated comorbidities also led 
to   death and prolonged hospital stay. Only in few cases, death occurred due to 
DKA.  Associated comorbidities and   complications led to more mortality. In this 
study most of patients with single comorbidity was selected. More than one 
comorbid illness can confound the mortality risk, hence patients with more than 
one comorbid illness not included in this study. 
  Among 16 deaths most of them had associated with other comorbid 
illness.5 patients    had suffered from coronary artery disease. Severe sepsis 
occurred in 7 died patients.3 patients had CKD.  
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In this study  58% had diabetes of less than 5 years duration,32% had 5 to9 
years duration;10% had  diabetes of more than 10 years .New onset diabetes was 
included in <5year duration category. In this study diabetes with more than 5yrs; 
13 deaths occurred. 14 patients had prolonged hospital stay. Patients with 
prolonged duration of diabetes have more mortality and morbidity61.They had 
prolonged hospital stay due to more complications 62 .This association was 
statistically significant with  
p value <0.001. 
Diabetes with micro albuminuria was observed in 28 patients; it was 
associated with morbidity and mortality of DKA. 13patients with prolonged 
hospital stay more than 2 week had micro albuminuria. Among total 16 death; 9 
patients had micro albuminuria. 
In this study patients with oral   anti diabetic drugs had high mortality and 
prolonged hospital stay>2week and complications. Among total 16 deaths   , 11 
were on oral diabetic drugs. 4death were observed in patients were taken both 
insulin and oral drugs.   Patients were on insulin; 1 death observed. So patients 
with oral antidiabetic drugs had more mortality compared to insulin .Association 
was statistically significant with p value <0.001.In a similar study; Diabetic 
ketoacidosis and clinical outcome   conducted by department of family medicine 
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Israel; similar results were obtained .Patients with oral drugs were prone to more 
complications 
Among patients with DKA   blood sugar values ranged from 380-659. 
Mortality increased with high blood sugar value .More death   were observed 
when    blood sugar value more than 500 mg/dl. One death was   seen in blood 
sugar value less than 500 mg/dl.15 death occurred in patients with RBS more 
than 500mg/dl. Prolonged hospital stay was observed in17 patients with RBS   
value   morethan63500 mg/dl. Relation between RBS and mortality was 
statistically significant with pvalue<0.001. 
According to PH value, serum bicarbonate levels   patients were classified 
into mild, moderate, severe acidosis. PH VALUE 64 more than7.25 with mild 
acidosis were occurred among 35 patients.PH less than7 with severe acidosis 
occurred in 8 patients.57 patients had pH value ranged from 7 to7.25 grouped into 
moderate acidosis. Among the patients with severe acidosis 4 patients were died. 
More severe the acidosis more complications were observed .In this study more 
patients presented with moderate acidosis, among them 10 death occurred.  
Association between severity of acidosis and mortality   was statistically 
significant with p value <0.001 
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There may be many shortcomings in this study. But this study will 
definitely give us a fair idea of the risk factors and prognosis of DKA in the rural 
Indian population.   
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SUMMARY 
 In our study it was found, 
  Males are more commonly affected. 
  DKA common in type 1DM and also it can occur in type265 diabetes. 
 Most important precipitating factors are noncompliance to drug ,inadequate 
insulin  therapy, infections66 followed by drugs like steroids, alcohol ,acute 
stressful events like MI,  STROKE 
 Associated comorbid illness   like stroke, MI, CKD cause  more mortality 
and complications in DKA patients 
 DKA have many complications like   sepsis, electrolyte disturbances, 
metabolic encephalopathy, respiratory failure67, severe acidosis etc. These 
complications cause   more mortality and prolonged hospital stay contribute 
to morbidity. 
  Diabetic patients with prolonged duration had significant mortality and 
morbidity, they were prone for complications. 
  Patients with severe acidosis had more mortality and more complications. 
  Patients with high blood sugar value   had high mortality and morbidity. 
  Patients   with oral anti diabetic drugs had significant mortality and 
morbidity, compared to insulin therapy. 
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CONCLUSION 
Diabetic ketoacidosis is an important acute complication 68  of diabetes. 
Precipitating   factors include   omission of insulin, noncompliance to drugs, 
infections69, sepsis,   myocardial infarction, stroke ,other drugs like steroids, 
alcoholism etc. DKA have multiple complications   ; that can led to death 
and prolonged hospital stay. Complications include sepsis, respiratory 
failure, electrolyte abnormalities, acidosis   , altered sensorium etc. 
Treatment mainly includes adequate fluid   management, insulin 
administration, and correction of electrolyte abnormality .Identification and 
treatment of precipitating factors are more important .Patient education70  
plays a crucial role in prevention of DKA.  
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ANNEXURE 
1) PROFORMA 
2) Consent Form 
3) MASTER CHART 
 
 
  
  
PROFORMA 
1) NAME OF THE PATIENT 
2) AGE 
3) SEX 
4) IP NUMBER 
5) ADDRESS 
  
HISTORY: 
.MODE OF ONSET 
.DURATION OF DIABETES 
 GENERALISED WEAKNESS 
FATIGUE 
NAUSEA AND VOMITING 
ABDOMINAL PAIN 
BREATHLESSNESS 
ALTERED SENSORIUM 
ANY FOCUS OF INFECTION 
FEVER 
ON REGULAR MEDICATION/NOT 
PAST HISTORY 
 DIABETES 
 HOW LONG 
 TREATED OR NOT 
 WHICH MEDICATION 
 DOSE 
 
 HYPERTENSION,CKD ,MI,CVA,COPD 
 OTHER MEDICATIONS 
 
CLINICAL EXAMINATION 
Vitals 
General appearance 
Sign of acidosis----shallow/rapid breathing 
Sign of dehydration---weak and rapid pulse 
Dry skin 
Fruity/acetone smell to breath 
SYSTEM EXAMINATION 
RESPIRATORY SYSTEM 
CVS  
ABDOMINAL EXAMINATION 
CNS 
INVESTIGATIONS 
CBC 
RBS 
RFT 
ELECTROLYTES 
LFT 
URINE ANALYSIS 
URINE ACETONE 
ECG 
CHEST X –RAY 
URINE ANALYSIS 
URINE CULTURE 
ABG 
 
  
ABBREVATIONS 
BMI  - BODY MASS INDEX 
BP  - BLOOD PRESSURE 
CAD  - CORONARY ARTERY DISEASE 
CKD  - CHRONIC KIDNEY DISEASE  
CVA  - CEREBRO VASCULAR ACCIDENT 
DKA  - DIABETIC KETO ACIDOSIS  
DM  - DIABETETS MELLITUS 
GLP-1 - GLUCAGONLIKE PEPTIDE–1 
LRI  - LOWER REPIRATORY TRACT INFECTION 
MI  - MYOCARDIAL INFRACTION 
OHA  - ORAL HYPOGLYCEMIC AGENTS 
PR  - PULSE RATE  
SGLT-2  - SELECTIVE SODIUM-GLUCOSE TRANSPORTER-2  
TZD  - THIOZOLIDINEDIONES 
UTI  - URINARY TRACT INFECTIONS 
INFORMED CONSENT FORM 
 
Study Title ___________________________________________________________________________ 
Study Number ________________________________________________________________________ 
Subject's Full Name ____________________________________________________________________ 
Date of Birth/Age______________________________________________________________________ 
Address ______________________________________________________________________________ 
 
1. I confirm that I have read and understood the information sheet dated for the above study and have 
had the opportunity to ask questions.  
OR I have been explained the nature of the study by the Investigator and had the opportunity to ask 
questions 
2. I understand that my participation in the study is voluntary and that I am free to withdraw at any time, 
without giving any reason and without my medical care or legal rights being affected. 
3. I understand that the sponsor of the clinical trial/project, others working on the Sponsor's behalf, the 
Ethics Committee and the regulatory authorities will not need my permission to look at my health 
records both in respect of the current study and any further research that may be conducted in relation 
to it, even if I withdraw from the trial. However, I understand that my Identity will not be revealed in 
any information released to third parties or published. 
4. I agree not to restrict the use of any data or results that arise from this study provided such a use is 
only for scientific purpose(s) 
5. I agree to take part in the above study 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: _________________ 
 
Signatory's Name ______________________________________ Date __________________________ 
 
Signature of the Investigator _____________________________ Date __________________________ 
 
Study Investigator's Name ________________________________ 
 
Signature of the Witness ________________________________ Date __________________________ 
 
Name of the Witness 
LRI
soft 
tissu
1 MARI 54 F <1 no Y no Y no no no 2 6 Y no no Y y N N N N N N N N 56 152 24.2 y 78 16 h y 14000 450 42 1.4 136 3.4 y y N moderate 10 7.02 DEATH N
2 Parvathy 60 f <1 no no no Y no no no 2 7 y Y no y y N N y N N N N N 68 162 25.9 N 90 18 N N 9900 530 78 2.9 136 3.9 y N N moderate 12 7.22 >2 y N
3 JANANI 17 F <1 no no no no no no no 1 3 N y no no N N N N y y N N N 50 164 18.6 y 102 22 N N 10500 512 38 1.2 128 3.5 N N N acidosis 15 7.3 <2 Y N
4 SUKANYA 15 F <1 no no no no no no no 1 3 N Y no no N N N N N N N N N 45 164 16.7 y 88 18 n N 4560 490 34 1.1 138 3.9 N N N moderate 12 7.2 <1 Y N
5 alagammal        16 f <1 y no Y no no no Y 1 2 N Y no no N N N N N N N N N 52 160 20.3 y 88 18 N N 8900 540 34 1.3 132 3.2 N N N moderate 11 7.12 <1 Y N
6 PETCHI 59 f <1 no no no no no no no 2 6 N no no Y N N N y N y Y N N 62 154 26.1 N 90 16 N N 11200 428 86 1.8 134 3.9 y N N mild 15 7.3 >2 Y y
7 KALYANI 57 f <1 no no no no no y no 2 7 Y no no Y N y N N N N N N N 62 162 23.6 y 104 22 HIGH N 7890 470 46 1.2 130 4.5 N N N mild 16 7.28 <2 Y N
8 SUBBU 62 f <1 no no no Y no no no 2 5 y no no no N N N N N N N N N 68 172 23.0 y 78 16 N N 5678 560 38 0.9 132 3.6 N N N mild 15 7.3 <2 Y N
9 Kali 65 f >1 no no no no no y no 2 6 N no no Y N y N N N N N N N 68 160 26.6 y 84 16 N N 11280 380 52 1.8 134 3.9 N N N moderate 12 7.22 >2 Y N
10 Athiselvi 47 f >1 no Y no no no no no new2 0 Y no no no N N N N N N N N N 54 164 20.1 y 92 24 N N 9980 460 34 1.4 134 4.2 N N N moderate 12 7.2 >2 Y N
11 shanmugammal 56  f <1 no no no Y no no no 2 6 N Y no no N N N N N N N N N 68 164 25.3 N 88 16 N N 6780 458 48 0.8 136 3.9 N N N mild 15 7.3 <1 Y N
12 abirami 20 f >1 y Y y no no no y 1 5 y y no no N N N N N N N N N 46 156 18.9 y 98 22 HIGH y 13400 606 68 3.4 134 2.8 y N N SEVERE 6 6.02 DEATH y
13 manjula 45 f >1 no no no no no no no 2 2 N no no y N N Y N N N Y N N 66 152 28.6 N 88 16 N N 6789 620 60 2.3 135 4.2 N N N moderate 12 7.2 <1 y N
14 esakiammal 59 f <1 no Y no Y no no no 2 8 N no no y N N Y N N N Y N N 58 160 22.7 Y 78 16 N N 10890 560 58 1.8 134 4.5 y N N mild 16 7.29 >2 y N
15 susheela 58 f <1 y y y no no y no 2 6 N no no y N N N Y N N N N N 56 168 19.8 N 78 18 N y 12300 540 86 3.4 134 4.6 N N N mild 15 7.26 >2 Y N
16 kovilammal      80 f >1 no no no y no no no 2 16 N no no Y N y N N y N y N N 63 164 23.4 N 88 24 N N 5679 490 42 1.8 136 4.7 N N N mild 16 7.28 >2 Y y
17 mariammal   50 f <1 y no no Y no no no 2 3 Y no no Y N N N N N N N N N 64 172 21.6 Y 88 18 N N 7890 460 46 1.4 135 5.3 y N N moderate 12 7.2 <1 Y N
18 lalitha 55 F >1 no no no no no no no 2 1 N no no Y N N N Y N N N N N 64 158 25.6 N 88 18 N N 6780 560 94 2.8 136 4.2 N N N mild 15 7.28 <1 y N
19 ranjithm 16 F <1 no y y no y no no 1 4 y Y no no N N N N N N N N N 46 154 19.4 Y 102 22 HIGH y 12400 568 38 0.8 134 4.3 N N N moderate 11 7.1 >2 y N
20 bhadrakali 18 f >1 no no y no no no no new1 0 Y no no no N N N N N N N N N 64 160 25.0 y 88 16 N N 8790 560 42 0.9 134 4.1 N N N moderate 12 7.2 <2 Y N
21 muthulakshmi 48 F <1 no no no Y no no no 2 3 y no no y N N N N N N N N N 64 160 25.0 y 78 18 N N 9800 456 52 1.9 134 5.1 y N N moderate 11 7.24 <1 y N
22 selvi 22 F <1 no Y Y no no no no 1 4 N Y no no N N N y N N N N N 50 168 17.7 y 96 24 high Y 16070 560 64 2.1 124 3.8 N N N SEVERE 6 6.22 >2 y y
23 mery 48 F <1 no no no no no no no 2 4 Y no no no N N N N N N N N N 64 169 22.4 Y 88 18 N N 8560 565 52 2.1 134 3.9 N N N mild 15 7.28 <1 Y N
24 vijayakumari   63 F <1 no no no no no no no 2 3 N no no Y N N N N N N N N N 64 174 21.1 U 78 14 N N 5670 650 42 1.4 136 6.2 y N N moderate 10 7.1 >2 Y N
25 Satyh path     16 F <1 no no no no no no no 1 2 N Y no no N N N N N N N N N 48 154 20.2 y 86 18 N N 8900 460 46 1.2 136 3.9 y N N mild 15 7.28 >2 Y N
26 guruvammal 67 F >1 no Y Y Y no no no 2 12 Y no Y Y Y N N N N N N N N 62 152 26.8 N 92 24 HIGH y 14060 520 64 2.3 130 4.9 y y N moderate 10 7.02 DEATH y
27 mariammal    53 F >1 no no no no no no no 2 6 Y no Y Y N N N N y y N N N 62 160 24.2 y 88 16 N N 8750 530 43 1.2 132 5.2 N N N mild 16 7.3 <1 Y N
28 rajalekshmi 54 F <1 no no no no no no no 2 1 N no no Y N N N N N N N N N 62 156 25.5 N 82 18 N N 7690 480 38 1.3 132 5.2 N N N moderate 11 7.24 <1 Y N
29 fathima 22 f <1 y y no no no no Y 1 3 y y no no N N N N N N N N N 62 164 23.1 y 96 24 high N 8900 490 46 1.4 136 3.8 N N N moderate 12 7.12 <2 y N
30 nancy 18 f >1 no Y Y no no no no 1 2 N Y no no N N N N N N N N N 52 157 21.1 N 94 18 HIGH N 5680 460 42 1.3 136 3.9 N N N SEVERE 7 6.22 >2 Y y
31 BANU 19 F <1 no no no Y no no no 1 4 y y no no N N N N N N N N N 48 154 20.2 Y 88 18 N N 10200 530 48 1.4 134 4.2 N N N mild 16 7.3 <1 y N
32 Saritha 48 F .>1 y no no no no no no new2 0 Y no no no N N N N N N N N N 48 152 20.8 y 108 24 high N 8870 520 46 1.2 132 3.2 N N N moderate 12 7.24 <1 y N
33 RAJAMMAL 75 F >1 no y no no no no Y 2 8 N no Y y y y N N N N y N N 56 158 22.4 y 92 16 N N 7990 515 48 1.4 132 4.8 y N N SEVERE 8 6.02 >2 y y
34 MEENACHI    72 F <1 no no no Y no no no 2 6 y no no y Y N N N N N N N N 67 156 27.5 y 88 22 N y 18900 590 64 2.4 126 4.3 y y N moderate 12 7.24 >2 y N
35 SARASWATHY  65 F >1 y no y no no no no 2 4 N no no y N N N N N N N N N 60 168 21.3 y 92 22 N N 5690 650 48 1.8 126 5.7 y N N severe 8 6.28 >2 y y
36 ASANFATH     18 F <1 y no no no Y no no 1 3 Y y no no N N N N N N N N N 60 166 21.8 y 84 18 N N 8790 601 46 1.2 132 4.2 N N y mild 17 7.3 <2 y y
37 janath 16 f <1 y no y no no no no 1 2 N y no no N N N N N N N N N 59 148 26.9 N 78 18 N N 7890 560 44 1.4 132 3.9 N N N moderate 12 7.22 <1 Y N
38 muppidati          68 f >1 no no y no no y no 2 12 y no no y Y N N N N N N N N 59 165 21.7 N 70 18 N N 8960 650 34 1.4 134 6.2 y N y moderate 10 7.1 DEATH N
39 pitchammai 56 f <1 no no no no no no no 2 4 y no no no N N N N N N N y N 59 162 22.5 N 92 18 high N 7850 620 38 1.4 136 4.6 N N N mild 16 7.29 <1 Y N
40 banumaty 58 f <1 y y y no no no no new 2 0 y no no no N N N N N N N N N 59 164 21.9 N 78 18 N N 6789 560 48 1.5 134 5.2 N N N moderate 12 7.1 <1 y N
41 Ramalachmi  18 f <1 no y no no no no no 1 6 N Y no no N N N N N N N N N 58 149 26.1 N 90 16 N N 7840 480 42 1.5 134 3.2 N N N mild 17 7.3 <1 y N
42 parumma 48 f >1 no no no no no no no NEW2 0 Y no no no N N N N N Y N N N 46 154 19.4 Y 84 18 N N 7869 450 42 1.4 134 3.9 N N N mild 16 7.3 <1 Y N
43 sonydas 55 male >1 y no no no no no no NEW2 0 Y no no no N N N N N N N y y 58 159 22.9 N 68 16 N N 8760 460 46 1.4 132 4.2 N N N mild 15 7.3 <1 Y N
44 petchidevar 65 m >1 no no no no no y no 2 7 y no no y N N N y N N N y N 58 170 20.1 y 106 22 HIGH N 22030 520 86 2.3 132 4.6 y N N mild 16 7.29 >2 y N
45 RAMASAMY 70 m >1 no y y no Y no no 2 12 N no Y no y N N N N N N N y 58 164 21.6 y 86 16 N y 14590 659 42 1.4 134 5.2 N N N moderate 10 7.2 DEATH y
46 MOHAN 52 m <1 no no no no no no no 2 10 y no no y N N N N y y N Y Y 58 164 21.6 Y 88 18 high N 7680 480 44 1.3 136 4.5 N N N moderate 12 7.24 >2 y N
47 MURUGAN 62 m <1 y no no no no no no 2 3 N no no y N N N N  N N N Y y 58 164 21.6 y 88 18 N N 8790 560 54 1.9 134 4.6 y N N mild 15 7.28 DEATH N
48 chelladurai 50 m <1 no no no no no no no 2 3 y no no y N N N N N N N Y N 58 168 20.5 y 83 16 N N 9860 560 50 1.2 136 4.8 N N N moderate 12 7.24 <1 y N
49 mariappan 65 M <1 no y no no no no Y 2 4 N no Y y N N N y N N N N y 56 150 24.9 y 98 18 N N 9870 630 78 1.8 134 6.2 y N N moderate 10 7.22 <1 y N
50 pandiaraj 70 M <1 no y no no no no no 2 5 y no Y no Y N N N y N N N y 56 160 21.9 N 88 24 N N 14320 580 56 1.8 136 4.3 N N N severe 8 6.03 >2 Y y
51 kankaraj 47 M <1 y no y no no no no 2 16 y no no y N N N N N N N Y y 56 148 25.6 N 88 16 N N 8690 540 42 1.4 128 4.3 N N N mild 15 7.3 <1 Y N
52 mani 40 M >1 no no no no no y no 2 2 N no no y N N N N N N N Y N 56 150 24.9 Y 88 18 N N 8970 560 46 1.3 136 3.2 y N N moderate 10 7.12 <2 y N
53 murugan 55 M >1 no no no no no no Y 2 2 N no no y Y N N N N N y N N 56 160 21.9 y 88 28 N N 7850 546 56 1.9 132 3.1 y N N severe 7 6.03 >2 y y
54 RAMAR 65 M <1 y y no no no no no 2 2 Y no Y N N N Y N N y N N 56 148 25.6 y 78 18 N N 9870 620 84 3.8 134 5.3 y N N moderate 12 7.23 DEATH N
55 DURAIRAJ 58 M <1 no no no no no no no 2 4 N no no y N N N N N N N N N 56 152 24.2 Y 94 22 high N 8970 480 46 1.5 136 4.4 N N N mild 16 7.3 <2 Y N
56 muthu 48 M <1 y no no no no no no new 2 0 Y no no no y N N N N N N Y Y 56 154 23.6 Y 86 18 N N 9800 578 48 1.4 134 4.6 N N N moderate 12 7.22 <1 Y N
57 MURUGESAN 54 M >1 no no no no Y no no 2 5 y no Y no N N N N Y N N Y N 56 160 21.9 y 78 16 HIGH y 18790 532 54 2.1 134 2.8 N N N moderate 10 7.12 >2 Y N
58 PAPANASAM 54 M .>1 Y Y Y no no y no 2 4 y no no y N N N N N Y N y Y 56 164 20.8 N 86 18 N N 7860 523 58 1.9 126 4.6 N N N moderate 11 7.23 <2 Y N
59 RAMASAMY 68 m <1 y no no no no no no 2 10 N no no y N Y N N N N N Y N 56 159 22.2 N 88 18 N N 8765 620 56 1.8 132 4.7 N N N moderate 12 7.2 DEATH N
60 beeran 56 m >1 Y Y Y no Y no no 2 4 N no no Y N N N N N Y N Y y 56 162 21.3 Y 88 24 N N 9870 570 54 1.4 134 3.2 N N N mild 16 7.29 >2 Y N
61 surendren 62 m >1 no y no no no y no 2 3 y no no y N N N N Y N N N y 56 172 18.9 y 88 22 N N 7869 470 48 1.4 124 4.5 N N N moderate 12 7.22 >2 y N
62 esakimutu 56 m <1 y no no Y no no no 2 7 y no no y N N N N N N N N Y 56 158 22.4 N 84 16 N y 22100 563 88 1.8 132 4.6 y N N moderate 10 7.12 >2 Y N
63 Najipkhan 72 m >1 no no no no no no no 2 14 N no no y N N N N N N N N N 54 156 22.2 N 78 18 N N 6780 560 43 1.4 136 4.7 y N N moderate 12 7.23 DEATH N
64 mydeen 45 m <1 y no no no no no no 2 1 y no Y N N N N Y N N y N 54 160 21.1 N 92 22 N N 9809 490 47 1.4 132 4.6 N N N moderate 12 7.22 <2 Y N
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65 Prem 48 m <1 y no no no no no no 2 2 y no no y N N N N N N N N y 54 162 20.6 y 86 18 N N 8970 489 48 1.4 132 4.7  N N N moderate 12 7.23 <1 y N
66 Nambirajan 56 m <1 no no no no no no Y 2 6 N no no y N N N N N N N N Y 52 153 22.2 N 78 16 N N 8760 482 42 1.5 128 5.1 N N N moderate 12 7.23 <1 y N
67 muthu 52 m <1 no no y no no no no new2 0 Y no no N N N N N N N N N 52 159 20.6 N 88 20 N N 7690 480 43 1.4 134 5.3 y N N mild 15 7.28 <1 y N
68 Raghu 62 m <1 y y y no no y no 2 6 y no no y N N N N N N N N Y 50 148 22.8 y 88 18 N Y 19870 560 56 2.2 132 4.6 y N y severe 8 6.04 DEATH y
69 samiduri 67 m >1 y y no no no no no 2 6 N no no N N N N N N N N Y 50 156 20.5 y 92 22 N N 7124 530 46 1.7 134 2.9 N N N mild 16 7.3 <2 Y N
70 sahulhameed 72 m >1 y y y no no no no 2 6 Y no no y Y N N N N N Y N Y 48 146 22.5 y 86 16 N N 7650 520 42 1.4 136 4.3 N N N moderate 12 7.23 DEATH y
71 kalyanasundaram 68 m >1 y y y no no no no 2 7 y no no N N N N N N N N 48 150 21.3 N 103 22 N y 18940 510 56 1.9 134 4.6 y N y moderate 10 7.22 DEATH y
72 vadivel 62 m <1 no no no no no no no 2 2 N no no N N N y N N N N 48 150 21.3 N 86 16 N N 8960 540 88 3.9 136 5.9 N N N moderate 11 7.12 DEATH N
73 chermakani 52 m >1 y no no no no no no NEW2 0 Y no no N N N N N Y N N 48 152 20.8 N 88 16 N N 9510 460 46 1.5 134 3.2 N N N moderate 12 7.12 <1 Y N
74 CHINNADURAI 77 m >1 y no no no no y no 2 10 N no Y y N N N N N N N N 48 146 22.5 N 86 16 N Y 21890 520 64 2.1 136 4.6 y N Y moderate 10 7.24 DEATH N
75 esakimutu 56 m <1 y no no no no no no 2 2 y no Y y N N N N N N N N Y 48 156 19.7 y 84 16 N N 6789 530 43 1.4 128 4.6 N N N moderate 12 7.22 <1 y N
76 KASIM 76 m >1 no no no Y no no no 2 12 N no Y N Y N N N N N Y Y 48 158 19.2 Y 82 14 N y 19800 540 68 1.9 134 4.6 y y N moderate 12 7.23 >2 Y N
77 CHINNAESAKI 58 m <1 Y no no no no no no 2 3 N no no Y N N N N N N N N Y 48 160 18.8 N 86 18 N N 5678 567 43 1.4 132 4.2 N N N mild 16 7.28 <1 Y N
78 THANKARAJ 67 m >1 no no no no no no no 2 4 N no no Y N N N N N N N N N 46 152 19.9 N 88 16 N N 6780 450 43 1.4 128 4.8 N N N mild 16 7.29 <1 Y N
79 MARIMUTU 53 m <1 no no no no no no no 2 2 Y no Y y N N N N N N N N Y 46 148 21.0 y 106 24 high N 7860 532 56 1.8 134 3.1 N N N moderate 12 7.12 <1 Y N
80 PANDIYAN 82 m >1 no Y no no no no no 2 6 N no no Y N N N N N N N N N 46 162 17.5 Y 96 20 N N 8970 580 56 1.8 136 4.3 y N N moderate 11 7.22 DEATH N
81 KOPALAN 58 m ,<1 y no no no no no no 2 7 Y no Y Y N N N N N N N N N 46 152 19.9 y 92 18 N N 7890 530 43 1.4 134 4.2 N N N moderate 10 7.1 <1 Y N
82 MURUGAN 52 m <1 y no no no no no no 2 6 N no no Y N N N N N N N N N 46 152 19.9 Y 78 24 N N 8760 510 44 1.4 132 5.1 N N N moderate 12 7.23 <1 y N
83 selvam 68 m >1 y no no no no no no 2 8 N no Y Y N N N N N N N N Y 46 156 18.9 Y 88 18 N N 8760 395 50 1.5 134 4.3 N N N moderate 12 7.22 <1 y N
84 saravanan 79 m >1 no y y no no no no 2 6 Y no no Y N N N N N N N N Y 43 152 18.6 y 88 18 N N 9870 590 45 1.3 136 4.5 N N N moderate 11 7.22 DEATH y
85 sorimutu 18 m <1 no no no no no no no 1 3 N y no no N N N N N N N N Y 38 148 17.3 Y 86 18 N N 6789 610 43 1.4 134 3.2 N N N moderate 10 7.23 <1 Y N
86 ponnuesaki 19 m <1 no no y no no no no 1 2 N y no no N N N N N N N N Y 42 142 20.8 88 16 N N 7890 567 42 1.4 136 2.9 N N N moderate 12 7.22 <2 Y N
87 arun 20 m <1 y no y no no no no 1 5 N y no no N N N N N N N N Y 48 145 22.8 y 90 18 N N 6789 567 44 1.4 134 5.2 N N N moderate 12 7.22 <1 Y N
88 vijay 18 m <1 no no no no no no no 1 4 Y y no no N N N N N N N Y N 50 156 20.5 Y 78 18 N N 4567 505 38 1.2 132 4.6 y N N mild 17 7.3 <1 Y N
89 shek muhamad 16 m <1 no no y no no no no 1 3 N y no no N N N N N N N N N 48 156 19.7 Y 90 18 N N 3456 460 43 1.3 134 4.3 N N N mild 16 7.28 <1 Y N
90 beeran 17 m <1 no y no no no no no 1 4 N y no no N N N N N N N N N 46 156 18.9 Y 86 18 N N 5678 450 44 1.3 136 4.5 N N N mild 16 7.28 <1 Y N
91 tamilhovan 20 m >1 no no y no no no no 1 5 N y no no N N N N N N N N N 49 158 19.6 Y 78 16 N N 7680 460 42 1.3 132 4.6 N N N moderate 12 7.22 <1 Y N
92 sankaran 22 m >1 no no y no no no no 1 5 N y no no N N N N N N N N N 55 162 21.0 Y 86 18 N N 6784 520 42 1.3 134 4.7 N N N mild 16 7.3 <1 Y N
93 selvam 17 m <1 no no y no no no no 1 2 Y y no no N N N N Y Y N N Y 52 167 18.6 Y 88 24 high N 7890 530 50 1.4 136 4.6 N N N moderate 10 7.12 >2 y N
94 pandiraj 14 m <1 no no y no no no no 1 4 N y no no N N N N N N N N Y 51 168 18.1 Y 82 14 N N 4560 430 46 1.5 126 3.6 N N N moderate 12 7.22 <2 Y N
95 amalan 18 m <1 no no y no no no no 1 3 Y y no no N N N N N Y N N N 52 159 20.6 Y 84 16 N N 6780 395 46 1.4 132 3.8 N N N moderate 12 7.23 <1 Y N
96 gobi 19 m >1 y no no no Y no no 1 4 Y y no no N N N N N N N N N 57 164 21.2 Y 80 18 N N 7680 394 42 1.4 134 3.8 N N N mild 17 7.3 <1 Y N
97 vasanth 20 m <1 y no y Y no no no 1 4 Y y no no N N N N N N N N N 46 157 18.7 N 88 20 N N 7650 520 43 1.5 136 3.9 N N N mild 15 7.28 <2 Y N
98 murugan 22 m >1 y no no no no no Y 1 1 N y no no N  N N N N N N N N 48 156 19.7 N 76 16 N N 8670 450 44 0.9 134 4.6 N N N mild 15 7.29 <2 Y N
99 vetrivel 22 m <1 no no no no no no no 1 2 y y no no N N N N N N N Y Y 49 169 17.2 N 78 16 N N 8790 520 46 0.8 134 4.6 N N N mild 16 7.28 <1 Y N
100 pandian 23 m <1 no no no no no no no 1 5 Y y no no N N N N N N N Y Y 52 159 20.6 N 72 18 N N 5678 389 38 1.2 134 4.9 N N N moderate 12 7.23 <1 Y N
Compli - Compliance || Temp - Temperature || SIRS - Systemic Inflammatory  response syndrome || TC - Total Count
